TY - JOUR
T1 - Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia
AU - Jamalpour, Maria
AU - Li, Xiujuan
AU - Gustafsson, Karin
AU - Tyner, Jeffrey W.
AU - Welsh, Michael
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from the Swedish Cancer Foundation, The Swedish Research Council, EXODIAB, and the Family Ernfors Fund. J.W.T. was supported by grants from the V Foundation for Cancer Research, the Gabrielle’s Angel Foundation for Cancer Research, and the NCI (5R00CA151457-04 and 1R01CA183947-01).
Funding Information:
We are grateful to Dr George Daley for suggestions, to Dr Martin Bergö for suggestions and providing the mutant Kras mice, and to Anna Bereza-Jarocinska for help with qPCR and western blotting. Maria Jamalpour, Xiujuan Li, Karin Gustafsson, and Michael Welsh performed the experiments. Maria Jamalpour, Karin Gustafsson, Jeffrey W Tyner, and Michael Welsh planned the experiments. All authors interpreted the results and Maria Jamalpour and Michael Welsh wrote the paper. All authors have made comments to the text. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from the Swedish Cancer Foundation, The Swedish Research Council, EXODIAB, and the Family Ernfors Fund. J.W.T. was supported by grants from the V Foundation for Cancer Research, the Gabrielle’s Angel Foundation for Cancer Research, and the NCI (5R00CA151457-04 and 1R01CA183947-01).
Publisher Copyright:
© 2018, © The Author(s) 2018.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - The Src homology-2 domain protein B is an adaptor protein operating downstream of tyrosine kinases. The Shb gene knockout has been found to accelerate p210 Breakpoint cluster region-cAbl oncogene 1 tyrosine kinase-induced leukemia. In human myeloid leukemia were tumors with high Src homology-2 domain protein B mRNA content, tumors were, however, associated with decreased latency and myeloid leukemia exhibiting immune cell characteristics. Thus, the aim of this study was to investigate the effects of Shb knockout on the development of leukemia in three additional models, that is, colony stimulating factor 3 receptor-T618I–induced neutrophilic leukemia, p190 Breakpoint cluster region-cAbl oncogene 1 tyrosine kinase-induced B-cell leukemia, and G12D-Kras-induced T-cell leukemia/thymic lymphoma. Wild-type or Shb knockout bone marrow cells expressing the oncogenes were transplanted to bone marrow–deficient recipients. Organs from moribund mice were collected and further analyzed. Shb knockout increased the development of CSF3RT618I-induced leukemia and increased the white blood cell count at the time of death. In the p190 Breakpoint cluster region-cAbl oncogene 1 tyrosine kinase B-cell model, Shb knockout reduced white blood cell counts without affecting latency, whereas in the G12D-Kras T-cell model, thymus size was increased without major effects on latency, suggesting that Shb knockout accelerates the development thymic lymphoma. Cytokine secretion plays a role in the progression of leukemia, and consequently Shb knockout bone marrows exhibited lower expression of granulocyte colony stimulating factor and interleukin 6 in the neutrophilic model and interleukin 7 and chemokine C-X-C motif ligand 12 (C-X-C motif chemokine 12) in the B-cell model. It is concluded that in experimental mouse models, the absence of the Shb gene exacerbates the disease in myeloid leukemia, whereas it alters the disease characteristics without affecting latency in B- and T-cell leukemia. The results suggest a role of Shb in modulating the disease characteristics depending on the oncogenic insult operating on hematopoietic cells. These findings help explain the outcome of human disease in relation to Src homology-2 domain protein B mRNA content.
AB - The Src homology-2 domain protein B is an adaptor protein operating downstream of tyrosine kinases. The Shb gene knockout has been found to accelerate p210 Breakpoint cluster region-cAbl oncogene 1 tyrosine kinase-induced leukemia. In human myeloid leukemia were tumors with high Src homology-2 domain protein B mRNA content, tumors were, however, associated with decreased latency and myeloid leukemia exhibiting immune cell characteristics. Thus, the aim of this study was to investigate the effects of Shb knockout on the development of leukemia in three additional models, that is, colony stimulating factor 3 receptor-T618I–induced neutrophilic leukemia, p190 Breakpoint cluster region-cAbl oncogene 1 tyrosine kinase-induced B-cell leukemia, and G12D-Kras-induced T-cell leukemia/thymic lymphoma. Wild-type or Shb knockout bone marrow cells expressing the oncogenes were transplanted to bone marrow–deficient recipients. Organs from moribund mice were collected and further analyzed. Shb knockout increased the development of CSF3RT618I-induced leukemia and increased the white blood cell count at the time of death. In the p190 Breakpoint cluster region-cAbl oncogene 1 tyrosine kinase B-cell model, Shb knockout reduced white blood cell counts without affecting latency, whereas in the G12D-Kras T-cell model, thymus size was increased without major effects on latency, suggesting that Shb knockout accelerates the development thymic lymphoma. Cytokine secretion plays a role in the progression of leukemia, and consequently Shb knockout bone marrows exhibited lower expression of granulocyte colony stimulating factor and interleukin 6 in the neutrophilic model and interleukin 7 and chemokine C-X-C motif ligand 12 (C-X-C motif chemokine 12) in the B-cell model. It is concluded that in experimental mouse models, the absence of the Shb gene exacerbates the disease in myeloid leukemia, whereas it alters the disease characteristics without affecting latency in B- and T-cell leukemia. The results suggest a role of Shb in modulating the disease characteristics depending on the oncogenic insult operating on hematopoietic cells. These findings help explain the outcome of human disease in relation to Src homology-2 domain protein B mRNA content.
KW - Myeloid leukemia
KW - Src homology-2 domain protein B
KW - cytokines
KW - lymphocytic/lymphoblastic leukemia
KW - signal transduction
UR - http://www.scopus.com/inward/record.url?scp=85046630095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046630095&partnerID=8YFLogxK
U2 - 10.1177/1010428318771472
DO - 10.1177/1010428318771472
M3 - Article
C2 - 29792386
AN - SCOPUS:85046630095
SN - 1010-4283
VL - 40
JO - Tumour Biology
JF - Tumour Biology
IS - 4
ER -